Tumor vaccine to begin clinical trials

December 05, 2003

Tampa, FL (Dec. 4, 2003) - A tumor vaccine developed at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, is headed for clinical trials with advanced breast-cancer patients in collaboration with the University of Nebraska Medical Center in Omaha, Introgen Therapeutics Inc. (NASDAQ: INGN) announced today.

The research is funded by the National Institutes of Health under the National Cancer Institute's Avon program.

The vaccine therapy, INGN 225, which has already been tested on small populations of lung-cancer patients, will be evaluated in a phase I/II study to treat patients with advanced breast cancer. An estimated 267,000 new cases of invasive and in situ breast cancer are expected to occur among women in the United States during 2003, resulting in an estimated 39,800 deaths.

"A goal of cancer immunologists is the development of viable cancer vaccines. As we progress into human trials for different types of cancer, we are moving closer to achieving that goal," said Dmitry Gabrilovich, M.D., Ph.D., one of the vaccine's developers at Moffitt and the USF College of Medicine.

Gabrilovich, an associate professor in Departments of Interdisciplinary Oncology and Molecular Biology and Biochemistry, further explained, "With the high incidence and mortality rates of breast cancer, we are eager to evaluate INGN 225 therapy in cancer patients with this devastating disease. We are excited because this vaccine approach may be applicable to many different kinds of cancer, not just lung and breast."

Moffitt researchers will prepare the vaccine and participate in immunologic evaluations. The trial with breast-cancer patients will be conducted at the University of Nebraska Medical Center. Enrollment will begin with patients with invasive breast cancer who will receive chemotherapy, in addition to the INGN 225 vaccine.

INGN 225 uses Introgen's Advexin drug to stimulate the patient's dendritic cells, which are then used as a therapeutic vaccine to immunize a patient against their cancer. Previously published preclinical data from Dr. Gabrilovich's group demonstrated that 60 percent of animals treated with INGN 225 were protected against tumor development. When dendritic cells were activated, 100 percent protection against tumors was achieved.

INGN 225 is already being evaluated in patients with small-cell lung cancer, also in a phase I/II study. This phase I/II study is funded by a grant from the American Cancer Society.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America.
-end-


University of South Florida (USF Health)

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.